Stock listing
NASDAQ:SEPN Septerna, Inc. Stock
Home listing (NASDAQ) of Septerna, Inc.
Follow Septerna, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:SEPN
$38.61 USD -0.84 (-2.1%)
Close on Nov 20, 2026
- Day range
- $38.23 – $39.89 USDNov 20, 2026
- Volume
- 374,248 sharesNov 20, 2026
- Market cap
- $1.84B USDAt the close on Nov 20, 2026 · price × 47.55M shares outstanding
- 52-week range
- $22.78 – $53.34 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $15.70M USDMedian day 344,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SEPN · Home | $38.61 USD | -0.84 (-2.1%) | 374,248 | $38.72 | $39.89 | $38.23 | $39.45 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SEPN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $38.61 | -0.84 | -2.1% | $38.72 | $39.89 | $38.23 | 374,248 | |
| $39.45 | -0.57 | -1.4% | $39.85 | $41.52 | $39.05 | 298,919 | |
| $40.02 | -1.65 | -4.0% | $41.67 | $41.67 | $39.28 | 271,754 | |
| $41.67 | -0.93 | -2.2% | $42.86 | $42.95 | $40.83 | 385,334 | |
| $42.60 | +0.74 | +1.8% | $41.66 | $42.88 | $40.60 | 337,791 | |
| $41.86 | -6.70 | -13.8% | $47.89 | $47.97 | $41.65 | 607,531 | |
| $48.56 | -3.78 | -7.2% | $51.90 | $53.34 | $45.26 | 1,127,403 | |
| $52.34 | +1.60 | +3.2% | $49.35 | $52.54 | $46.84 | 537,115 | |
| $50.74 | +1.89 | +3.9% | $49.86 | $50.82 | $48.07 | 713,674 | |
| $48.85 | +1.50 | +3.2% | $48.20 | $51.05 | $47.84 | 384,548 | |
| $47.35 | -0.53 | -1.1% | $47.90 | $48.08 | $45.96 | 533,933 | |
| $47.88 | +4.18 | +9.6% | $45.60 | $48.23 | $44.79 | 604,656 | |
| $43.70 | +0.50 | +1.2% | $43.53 | $44.58 | $42.22 | 307,509 | |
| $43.20 | -0.80 | -1.8% | $44.06 | $44.95 | $41.07 | 475,332 | |
| $44.00 | -1.23 | -2.7% | $45.00 | $45.43 | $43.68 | 223,449 | |
| $45.23 | +0.98 | +2.2% | $44.43 | $45.60 | $43.74 | 200,615 | |
| $44.25 | +0.11 | +0.2% | $43.51 | $45.08 | $41.92 | 380,134 | |
| $44.14 | +2.76 | +6.7% | $41.78 | $44.22 | $40.97 | 261,813 | |
| $41.38 | +0.97 | +2.4% | $40.42 | $41.95 | $38.39 | 279,428 | |
| $40.41 | -0.47 | -1.1% | $40.63 | $41.21 | $39.65 | 200,300 | |
| $40.88 | +0.12 | +0.3% | $40.72 | $41.77 | $39.70 | 251,100 | |
| $40.76 | +1.41 | +3.6% | $39.57 | $41.40 | $38.75 | 286,400 | |
| $39.35 | +2.97 | +8.2% | $36.46 | $39.55 | $36.25 | 418,300 | |
| $36.38 | +0.03 | +0.1% | $36.48 | $37.82 | $36.04 | 410,200 | |
| $36.35 | -1.10 | -2.9% | $37.47 | $37.47 | $35.09 | 234,100 | |
| $37.45 | +1.13 | +3.1% | $36.78 | $38.36 | $36.22 | 271,400 | |
| $36.32 | -0.095 | -0.3% | $36.00 | $37.28 | $34.36 | 370,000 | |
| $36.42 | -1.145 | -3.0% | $37.49 | $38.51 | $36.28 | 491,900 | |
| $37.56 | -0.81 | -2.1% | $38.32 | $38.41 | $37.25 | 207,600 | |
| $38.37 | +1.47 | +4.0% | $36.76 | $38.73 | $35.77 | 349,400 | |
| $36.90 | +0.90 | +2.5% | $35.47 | $37.09 | $34.66 | 745,400 | |
| $36.00 | +0.33 | +0.9% | $35.27 | $37.14 | $35.20 | 1,028,400 | |
| $35.67 | -2.20 | -5.8% | $37.97 | $38.69 | $35.60 | 490,400 | |
| $37.87 | +0.16 | +0.4% | $37.83 | $38.52 | $36.82 | 266,700 | |
| $37.71 | -0.34 | -0.9% | $38.84 | $39.11 | $37.31 | 395,400 | |
| $38.05 | -1.08 | -2.8% | $38.90 | $39.52 | $37.81 | 545,100 | |
| $39.13 | 0.00 | 0.0% | $39.13 | $39.85 | $38.49 | 209,600 | |
| $39.13 | -0.61 | -1.5% | $39.52 | $39.57 | $38.37 | 564,500 | |
| $39.74 | +1.97 | +5.2% | $37.61 | $39.78 | $37.03 | 338,300 | |
| $37.77 | -0.36 | -0.9% | $38.34 | $38.34 | $37.35 | 344,300 | |
| $38.13 | -0.32 | -0.8% | $38.41 | $38.81 | $37.49 | 293,000 | |
| $38.45 | -1.93 | -4.8% | $40.17 | $40.17 | $36.98 | 509,700 | |
| $40.38 | +1.84 | +4.8% | $38.78 | $41.09 | $38.74 | 412,000 | |
| $38.54 | -0.15 | -0.4% | $38.97 | $39.47 | $38.01 | 252,400 | |
| $38.69 | -0.81 | -2.1% | $39.28 | $39.48 | $37.88 | 448,200 | |
| $39.50 | +1.06 | +2.8% | $39.38 | $40.52 | $39.01 | 256,800 | |
| $38.44 | -0.42 | -1.1% | $39.15 | $40.24 | $37.92 | 304,900 | |
| $38.86 | -0.69 | -1.7% | $39.52 | $39.52 | $38.26 | 269,600 | |
| $39.55 | +1.04 | +2.7% | $38.66 | $39.95 | $38.51 | 356,000 | |
| $38.51 | +0.76 | +2.0% | $37.75 | $40.02 | $37.56 | 354,300 | |
| $37.75 | -0.22 | -0.6% | $37.37 | $38.43 | $36.60 | 338,700 | |
| $37.97 | +0.60 | +1.6% | $37.15 | $39.40 | $37.15 | 475,300 | |
| $37.37 | +0.62 | +1.7% | $36.15 | $38.06 | $36.01 | 309,900 | |
| $36.75 | -0.05 | -0.1% | $36.57 | $37.59 | $36.57 | 199,700 | |
| $36.80 | -0.70 | -1.9% | $37.72 | $38.20 | $36.46 | 241,500 | |
| $37.50 | -0.18 | -0.5% | $37.96 | $38.86 | $37.25 | 263,200 | |
| $37.68 | -0.47 | -1.2% | $38.15 | $38.57 | $37.24 | 264,000 | |
| $38.15 | -0.76 | -2.0% | $38.71 | $39.11 | $37.39 | 415,300 | |
| $38.91 | -1.56 | -3.9% | $40.25 | $40.95 | $38.74 | 385,900 | |
| $40.47 | +0.22 | +0.5% | $40.01 | $41.08 | $39.95 | 266,500 | |
| $40.25 | -1.05 | -2.5% | $41.08 | $41.36 | $40.12 | 168,500 | |
| $41.30 | +0.78 | +1.9% | $41.57 | $41.85 | $40.47 | 333,400 | |
| $40.52 | +0.52 | +1.3% | $39.76 | $40.90 | $38.96 | 520,500 | |
| $40.00 | -0.79 | -1.9% | $41.44 | $41.44 | $39.95 | 289,800 | |
| $40.79 | -3.14 | -7.1% | $43.15 | $43.62 | $40.24 | 429,900 |
- Ticker
- NASDAQ:SEPN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results
Latest deck · Nov 4, 2026
Investor Presentation (November 2026)
Investor deck · 37 slides
Latest news
Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results
Nov 9, 2026
Closed $52.34 (+3.2%) on Nov 10, 2026
Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting
Nov 4, 2026
Closed $47.88 (+9.6%) on Nov 4, 2026
Septerna to Participate in Upcoming Investor Conferences
Nov 3, 2026
Closed $43.70 (+1.2%) on Nov 3, 2026
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 10, 2026
Closed $38.51 (+2.0%) on Sep 11, 2026
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
Aug 25, 2026
Closed $41.30 (+1.9%) on Aug 25, 2026
Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
Aug 10, 2026
Closed $47.76 (+22.9%) on Aug 11, 2026
Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
Jun 8, 2026
Closed $30.41 (-2.4%) on Jun 8, 2026
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
May 11, 2026
Closed $24.84 (+5.4%) on May 12, 2026
Septerna to Present at Bank of America Securities Health Care Conference
May 5, 2026
Closed $24.13 (-2.8%) on May 5, 2026
Septerna, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 32 in all · newest Nov 9, 2026 · oldest 2024
- Decks
- 9 decks · latest Nov 4, 2026
Where Septerna, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SEPN · Home listing · This page | NASDAQ | United States | USD |
| BOATS:SEPN | BOATS | United States | USD |
Valuation
EV/sales 14.3× against a median of 5.0×: 4th lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.38B USD
- P/E
- Loss
- EV/sales
- 14.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.3×
- Gross margin
- Not reported
- Operating margin
- −76.2%
- Net margin
- −61.3%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.95
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Septerna, Inc. · NASDAQ:SEPN | US$1.84B | US$1.38B | n/a | 14.3× | n/a | 4.3× | −61.3% | 0.1× | 0.95 |
| Shanghai Henlius Biotech, Inc. Class H · HKEX:2696 | US$1.91B | US$2.36B | 14.7× | 2.1× | 12.3× | 2.8× | 11.7% | 0.9× | n/a |
| Trevi Therapeutics, Inc. · NASDAQ:TRVI | US$1.90B | US$1.60B | n/a | n/a | n/a | 6.3× | n/a | 0.0× | 1.22 |
| Biohaven Ltd. · NYSE:BHVN | US$1.87B | US$1.71B | n/a | n/a | n/a | n/a | n/a | n/a | 1.19 |
| BioCryst Pharmaceuticals, Inc. · NASDAQ:BCRX | US$1.86B | US$1.88B | n/a | 1.9× | n/a | n/a | −37.4% | n/a | 0.62 |
| Immunome, Inc. · NASDAQ:IMNM | US$1.85B | US$1.40B | n/a | n/a | n/a | 4.1× | n/a | 0.0× | 1.49 |
| Zymeworks Inc. · NASDAQ:ZYME | US$1.84B | US$2.08B | 42.5× | 7.8× | 40.6× | 7.1× | 16.3% | 1.3× | 0.69 |
| Vera Therapeutics, Inc. · NASDAQ:VERA | US$1.84B | US$1.53B | n/a | 149× | n/a | 5.5× | n/a | 0.2× | 1.13 |
| Hemab Therapeutics Holdings, Inc. · NASDAQ:COAG | US$1.84B | US$1.41B | n/a | n/a | n/a | 4.3× | n/a | 0.0× | 0.61 |
| Braveheart Bio, Inc. · NASDAQ:BRVE | US$1.84B | US$1.71B | n/a | n/a | n/a | 3.7× | n/a | 0.0× | n/a |
| Replimune Group, Inc. · NASDAQ:REPL | US$1.81B | US$1.60B | n/a | n/a | n/a | 8.8× | n/a | 0.5× | 0.78 |
| Median of the others | US$1.85B | US$1.66B | 28.6× | 5.0× | 26.5× | 4.9× | 11.7% | 0.1× | 0.96 |
Forecasts
9 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 59.22 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.20 · 3 analysts
- Revenue, year to Dec 2026
- 94.38M · 10 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jeffrey Finer | Chief Executive Officer and Co-Founder |
| Gil Labrucherie | Chief Financial Officer |
| Liz Bhatt | President and Chief Operating Officer |
| Mark A. Wilson | Chief Legal Officer |
| Daniel Long | Senior Vice President, Drug Discovery |
| Uwe Klein | Senior Vice President, Biological Sciences |
| Rajiv Patni | Chief Medical Officer |
| Samira Shaikhly | Chief People Officer |
Board
| Director | Role |
|---|---|
| Jeffrey Tong | Chairman of the Board |
| Abraham Bassan | Director |
| Alan Ezekowitz | Director |
| Bernard Coulie | Director |
| Jake Simson | Director |
| Jeffrey Finer | Chief Executive Officer and Co-Founder |
| Keith M. Gottesdiener | Director |
| Shalini Sharp | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · After close | +3.1% |
| Q2 2026 | Aug 10, 2026 · After close | +22.9% |
| Q1 2026 | May 11, 2026 · After close | +5.4% |
| Q4 2025 | Mar 26, 2026 | −1.4% |
| Q3 2025 | Nov 10, 2025 · Before open | −2.2% |
| Q2 2025 | Aug 11, 2025 · After close | −2.5% |
| Q1 2025 | May 15, 2025 · After close | −2.8% |
| Q4 2024 | Mar 27, 2025 | −0.7% |
| Q3 2024 | Nov 20, 2024 · After close | −3.2% |
| Q2 2024 | Aug 28, 2024 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 37 slides | Nov 4, 2026 |
| Investor Presentation (August 2026) | Investor deck | 31 slides | August 2026 |
| ENDO 2026 | Conference | 14 slides | Jun 13, 2026 |
| Investor Presentation (April 2026) | Investor deck | 41 slides | Apr 13, 2026 |
| Technical Presentation (March 2026) | Technical | 28 slides | Mar 2, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 30 slides | Jan 12, 2026 |
| Investor Presentation (September 2025) | Investor deck | 30 slides | Sep 3, 2025 |
| TD Cowen 45th Annual Health Care Conference 2025 | Conference | 27 slides | Mar 3, 2025 |
| J.P. Morgan Healthcare Conference 2025 | Conference | 26 slides | Jan 13, 2025 |
IPO
Priced at US$18.00 a share on Oct 24, 2024.
- Price
- US$18.00 a share
- Shares offered
- 16,000,000 shares of common stock
- Offering size
- US$288 million
- Underwriters' option
- Up to 2,400,000 more shares
- Underwriters
- J.P. Morgan, TD Cowen, Cantor, Wells Fargo Securities · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 2, 2024 |
| Filed publicly | Oct 2, 2024 |
| Amended twice | Newest Oct 24, 2024 |
| Shares registered with an exchange | Oct 22, 2024 |
| Declared effective by the SEC | Oct 24, 2024 |
| Final prospectus, with the price | Oct 25, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 25, 2024 |
| EFFECT · Notice that a registration is effective | Oct 24, 2024 |
| S-1MEF · Registration of more shares for the same offering | Oct 24, 2024 |
| CERT · Exchange's certificate of listing | Oct 24, 2024 |
| S-1/A · Registration statement, amended | Oct 24, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 22, 2024 |
| CORRESP · Letter to the SEC | Oct 22, 2024 |
| CORRESP · Letter to the SEC | Oct 22, 2024 |
| S-1/A · Registration statement, amended | Oct 21, 2024 |
| CORRESP · Letter to the SEC | Oct 15, 2024 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Oct 2, 2024 |
| S-1 · Registration statement | Oct 2, 2024 |
| UPLOAD · Letter from the SEC | Sep 24, 2024 |
| DRS/A · Draft registration statement, amended | Sep 12, 2024 |
| DRSLTR · Letter to the SEC with a draft | Sep 11, 2024 |
| UPLOAD · Letter from the SEC | Sep 5, 2024 |
| DRS · Draft registration statement | Aug 2, 2024 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 25, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 46.0M | 1.07M | 151.0K | 0 |
| Cost of revenue | 1.60M | |||
| Gross profit | 46.0M | 1.07M | 151.0K | |
| Research and development | 97.6M | 65.3M | 36.0M | 22.0M |
| Selling, general and administrative | 29.2M | 16.6M | 9.72M | 5.92M |
| Operating income | -68.3M | -80.8M | 2.08M | -28.0M |
| Depreciation and amortization | 1.60M | 1.40M | 800.0K | 577.0K |
| EBITDA | -66.7M | -79.4M | 2.88M | -27.4M |
| Income before tax | -48.9M | -72.3M | -48.9M | -27.7M |
| Income tax | 12.0K | -498.0K | 691.0K | |
| Net income | -48.9M | -71.8M | 4.18M | -27.7M |
| Earnings per share, basic | -1.10 | -7.26 | 0.29 | -1.42 |
| Earnings per share, diluted | -1.10 | -7.26 | 0.29 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 120.7M | 238.2M | 88.5M | 30.6M |
| Short-term investments | 270.4M | 112.7M | 0 | |
| Receivables | 10.4M | 171.0K | 151.0K | 0 |
| Current assets | 411.0M | 356.8M | 112.7M | 31.9M |
| Property, plant and equipment | 4.43M | 5.09M | 4.67M | |
| Total assets | 596.2M | 456.6M | 130.9M | 36.1M |
| Accounts payable | 10.3M | 3.20M | 2.64M | 3.07M |
| Current liabilities | 86.9M | 12.8M | 6.91M | 5.54M |
| Total debt | 23.6M | 25.5M | 12.6M | 710.0K |
| Total liabilities | 214.3M | 36.5M | 20.0M | 80.3M |
| Shareholders' equity | 381.9M | 420.0M | -38.4M | -44.2M |
| Shares outstanding | 44.8M | 44.4M | 3.17M | 19.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | 110.2M | -67.5M | -38.7M | -23.3M |
| Capital spending | -518.0K | -2.10M | -2.88M | -1.29M |
| Free cash flow | 109.7M | -69.6M | -41.6M | -24.6M |
| Cash from investing | -229.4M | -160.6M | 22.1M | -1.29M |
| Cash from financing | 1.69M | 377.8M | 74.5M | 30.1M |
| Share buybacks | -1.00K | -1.00K | -1.00K | |
| Change in cash | -117.5M | 149.7M | 57.9M | 5.46M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
All 180 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 4, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 25, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 11, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 30, 2026 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 26, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 13, 2026 | Current report | SEC |
| S-3ASR · Registration statement | Mar 10, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 9, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 9, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 9, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 2, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 29, 2025 | Management or board change | SEC |
| 8-K · Current report | Sep 3, 2025 | Current report | SEC |
| 8-K · Current report | Aug 21, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 8-K · Current report | Aug 4, 2025 | Management or board change | SEC |
| 8-K · Current report | Jul 2, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 9, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 3, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 18, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Jan 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 6, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 20, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 20, 2024 | Results | SEC |
| SC 13D · Big-stake notice | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 1, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 28, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Oct 25, 2024 | Offer document | SEC |
| 424B4 · Prospectus | Oct 25, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 25, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 24, 2024 | Insider trade | SEC |
| S-1MEF · Registration of more shares for the same offering | Oct 24, 2024 | Offer document | SEC |
| CERT · Exchange's certificate of listing | Oct 24, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Oct 24, 2024 | Offer document | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Oct 22, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 22, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 22, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Oct 21, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Oct 15, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 2, 2024 | Other filings | SEC |
| S-1 · Registration statement | Oct 2, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 24, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Sep 11, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Sep 11, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 5, 2024 | Other filings | SEC |
| DRS · Draft registration statement | Aug 2, 2024 | Offer document | SEC |
| D | Jul 13, 2023 | Other filings | SEC |
Cap table
Built by 6ix from Septerna, Inc.’s releases · as of Nov 4, 2026
- Common shares
- 47,549,223
- Fully diluted
- 47,549,223
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 47,549,223 | Nov 4, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 4, 2026 | 47,549,223 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Since at least Oct 24, 2024 |
| Rajiv Patni Other companies: BioXcel Therapeutics, Inc. (Director · Since at least Jan 15, 2025); Quince Therapeutics, Inc. (Director · Since at least Feb 15, 2024); Reata Pharmaceuticals Inc (EVP, Chief R&D Officer · Jun 12, 2023 – Sep 26, 2023 · Past); Portola Pharmaceuticals Inc (EVP, CMO · Feb 3, 2020 – Jul 2, 2020 · Past); Adamas Pharmaceuticals Inc (Chief Medical Officer · Jun 8, 2015 – Apr 8, 2019 · Past); Ocera Therapeutics Inc (Chief Development Officer · Sep 2, 2014 – May 7, 2015 · Past) | Chief Medical Officer · Since at least Aug 24, 2026 |
| Jeffrey Tong Other companies: Maze Therapeutics, Inc. (Director · Jan 30, 2025 – Jan 30, 2025 · Past); Rapport Therapeutics, Inc. (Director · Jun 6, 2024 – Jun 6, 2024 · Past); Nurix Therapeutics, Inc. (Director · Jul 23, 2020 – May 6, 2021 · Past) | Chairman of the Board · Since at least Oct 24, 2024 |
| Keith Gottesdiener Other companies: Prime Medicine, Inc. (See Remarks, Director · Oct 19, 2022 – May 8, 2025 · Past); Rhythm Pharmaceuticals, Inc. (CEO & President, Director · Oct 4, 2017 – Mar 9, 2020 · Past); Intercept Pharmaceuticals Inc (Director · Jul 19, 2016 – Nov 8, 2023 · Past) | Director · Since at least Sep 25, 2025 |
| Liz Bhatt Other companies: eFFECTOR Therapeutics Inc (Director · Aug 25, 2021 – Jun 13, 2024 · Past); Applied Molecular Transport Inc (Chief Bus. & Strategy Officer · Jun 4, 2020 – Feb 15, 2022 · Past); Achaogen Inc (Chief Operating Officer · Jul 26, 2018 – Feb 21, 2019 · Past) | President and Chief Operating Officer · Since at least Oct 24, 2024 |
| Alan Ezekowitz Other companies: Organon & Co. (Director · Since at least Jun 2, 2021); Fulcrum Therapeutics, Inc. (Director · Since at least Jul 17, 2019) | Director · Since at least Oct 24, 2024 |
| Gil Labrucherie Other companies: Rezolute, Inc. (Director · Since at least Jan 23, 2024); Acelyrin, Inc. (CFO and CBO · Oct 4, 2023 – Aug 31, 2024 · Past) | Chief Financial Officer · Since at least Jan 6, 2025 |
| Jae B Kim Other companies: Design Therapeutics, Inc. (Chief Medical Officer · Mar 13, 2024 – Mar 13, 2024 · Past); Avidity Biosciences, Inc (Chief Medical Officer · Jul 27, 2020 – Feb 2, 2021 · Past) | Chief Medical Officer · Since at least Oct 24, 2024 |
| Bernard Coulie Other companies: Pliant Therapeutics, Inc. (Director · Since at least Jun 2, 2020) | Director · Since at least Oct 24, 2024 |
| Jake Simson Other companies: Janux Therapeutics, Inc. (Director · Since at least Jun 11, 2026) | Director · Since at least Nov 5, 2026 |
All 18 people
| Person | Seat |
|---|---|
| Shalini Sharp Other companies: Organon & Co. (Director · Since at least Nov 5, 2026) | Director · Since at least Nov 5, 2026 |
| Abraham Bassan | Director · Since at least Nov 5, 2026 |
| Daniel Long | Senior Vice President, Drug Discovery · Since at least Oct 24, 2024 |
| Jeffrey Finer | Chief Executive Officer, Director · Since at least Apr 2, 2025 |
| Mark A. Wilson | Chief Legal Officer · Since at least Jan 8, 2026 |
| Ran Xiao | Interim CFO · Oct 24, 2024 – Oct 24, 2024 · Past |
| Samira Shaikhly | Chief People Officer · Since at least Jun 30, 2026 |
| Uwe Klein | Senior Vice President, Biological Sciences · Since at least Aug 7, 2025 |
Log in to ask 6ix AI your own questions about Septerna, Inc.